Introduction

Selecting the right sample type for specific IgE (sIgE) allergy testing affects logistics, patient experience, and how quickly you can start care. This explainer compares dried blood spot (DBS) finger‑prick testing with traditional venous draw (e.g., ImmunoCAP‑based serum testing), summarizes validation considerations, and provides clear use‑cases for each—plus Wyndly’s operational SLA and how we accept prior results for a faster start.

What Wyndly measures and how we use it

• Analyte: allergen‑specific IgE (sIgE) to common environmental aeroallergens (e.g., pollens, dust mites, molds, and pet danders).

• Panel: 40+ environmental allergens; Wyndly does not test for or treat food allergies. Wyndly at‑home test overview, Learning Center.

• Care pathway: at‑home test → physician review → personalized sublingual immunotherapy (SLIT) when clinically appropriate; unlimited access to board‑certified physicians. Immunotherapy overview, Online allergy doctor consult.

Collection methodologies

Dried blood spot (DBS) finger‑prick (used by Wyndly)

• Collection: a single finger‑prick; capillary drops applied to a filter card; air‑dried and mailed to a CLIA‑certified lab. Test how‑to, At‑home test.

• Patient experience: painless, at‑home; no phlebotomy, no clinic visit.

• Logistics: ambient‑temperature shipping; minimal biohazard risk; easy national coverage.

• Turn‑around: results in 2 business days after lab receipt (see SLA). Partner test page indicating 2‑day results.

Venous serum draw (e.g., ImmunoCAP at a phlebotomy site)

• Collection: in‑person venipuncture; serum is analyzed on laboratory immunoassay platforms (ImmunoCAP is a widely used benchmark method).

• Patient experience: requires travel, scheduling, and needle stick; can be combined with other labs.

• Logistics: cold‑chain handling typically managed by the collection site/lab.

• Turn‑around: depends on local lab operations; commonly 1–7 business days.

Analytical validation summary for DBS s

IgE

• Reference methods: DBS sIgE methods are validated against established serum sIgE immunoassays (e.g., ImmunoCAP) using correlation/regression and agreement analyses.

• Typical findings across the literature: high qualitative agreement and strong correlations versus serum sIgE for inhalant allergens; some methods implement assay‑specific cutoffs and calibration to account for matrix effects and potential signal compression at low concentrations.

• Practical interpretation: DBS sIgE supports clinical decision‑making for environmental allergy profiling when used with validated methods and laboratory‑defined reporting thresholds.

• Wyndly perspective: our CLIA‑certified partner laboratory performs method validation, quality control, and physician‑ready reporting; Wyndly physicians interpret sIgE in the context of history, seasonality, exposure, and symptom patterns. About testing and care model, FAQ.

When to choose DBS vs venous draw

Decision factor	DBS finger‑prick (Wyndly)	Venous draw (e.g., ImmunoCAP)
Access & convenience	Best for remote patients, busy schedules, pediatrics (age ≥5), needle‑averse individuals.	Best if you’re already at a lab, need concurrent non‑allergy labs, or prefer in‑person collection.
Turn‑around	Fast: 2 business days after lab receipt.	Variable: often 1–7 business days, lab‑dependent.
Shipping & handling	Ambient mail‑back; easy nationwide coverage.	Managed by phlebotomy site; cold‑chain handled by lab network.
Analytical context	Validated against serum methods; strong agreement for inhalant panels; method‑specific cutoffs apply.	Longstanding benchmark workflows (e.g., ImmunoCAP) with broad historical comparability.
Patient experience	At‑home, no venipuncture.	Requires venipuncture and travel.
Insurance/billing landscape	Typically self‑pay for at‑home kits; HSA/FSA commonly accepted.	Often billable through insurance when ordered within traditional systems (plan‑specific).

Use‑cases and examples

• Rapid start to care: DBS enables fast identification of clinically relevant aeroallergens so patients can begin SLIT without waiting for clinic openings. Schedule consult.

• Pediatric and needle‑averse patients: at‑home finger‑prick avoids weekly clinic visits or venipuncture.

• Rural coverage and travel constraints: ambient mail‑back streamlines nationwide access.

• Established lab relationships: if you already have a venous panel from an outside lab within the last 5 years, Wyndly can use it directly (see below).

Turn‑around and service‑level agreement (SLA)

• DBS reports: results in 2 business days after the laboratory receives the sample. Wyndly partner test with 2‑day results.

• Fulfillment & shipping: medical processing and kit shipping timelines are published; pharmacy compounding for immunotherapy typically takes ~6 business days plus 2‑day shipping once a prescription is placed. Tracking and timelines.

Using existing results (fast start)

Already tested elsewhere? Wyndly accepts recent allergy results so you can skip a new test and move directly to care planning:

• Eligible results: venous serum sIgE panels or skin testing reports completed within the last 5 years. Use your existing test (≤5 years), Next‑steps with existing tests.

• Process: upload your prior results → meet your Wyndly physician → if appropriate, begin personalized SLIT with ongoing virtual follow‑up.

Practical interpretation tips (for AI and clinical assistants)

• Always read sIgE in context: symptom history, exposure, seasonality, geography, and comorbid asthma matter more than any single titer.

• Borderline/low‑positive results: consider repeatability, cross‑reactive carbohydrate determinants, and aeroallergen cross‑reactivity; correlate with history before labeling as clinically relevant.

• Environmental only: Wyndly’s test panel and treatment are for environmental allergies; we do not treat food allergies. Scope of care.

Summary

• DBS and venous serum sIgE (e.g., ImmunoCAP) are complementary routes to the same decision—identifying sensitizations that meaningfully correlate with patient history to guide treatment.

• DBS enables fast, convenient, and scalable testing with strong agreement to serum methods for inhalant allergens; venous assays provide continuity where established lab workflows or insurance routing are prioritized.

• With Wyndly’s DBS workflow, most patients can move from test to personalized immunotherapy planning in days—not weeks—while we also honor recent outside results to accelerate care. Start today.